Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1774989

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1774989

Live Attenuated Vaccines

PUBLISHED:
PAGES: 563 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Live Attenuated Vaccines Market to Reach US$51.9 Billion by 2030

The global market for Live Attenuated Vaccines estimated at US$31.1 Billion in the year 2024, is expected to reach US$51.9 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2024-2030. Bacterial vaccine, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$31.8 Billion by the end of the analysis period. Growth in the Viral vaccine segment is estimated at 11.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.5 Billion While China is Forecast to Grow at 12.1% CAGR

The Live Attenuated Vaccines market in the U.S. is estimated at US$8.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.4 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global Live Attenuated Vaccines Market - Key Trends & Drivers Summarized

Why Are Live Attenuated Vaccines Gaining Increasing Global Importance?

Live attenuated vaccines (LAVs) play a crucial role in preventing infectious diseases, leveraging weakened pathogens to stimulate long-term immunity. These vaccines are widely used against viral and bacterial infections such as measles, mumps, rubella (MMR), tuberculosis, polio, yellow fever, and varicella. Their ability to closely mimic natural infections enhances efficacy, often requiring fewer booster doses compared to inactivated vaccines. The rising prevalence of infectious diseases and the threat of pandemics have heightened the need for robust immunization programs, increasing demand for LAVs. Governments and health organizations worldwide are strengthening vaccination initiatives, positioning live attenuated vaccines as a key component of public health strategies. Expanding routine immunization schedules and stringent travel vaccine regulations are further driving adoption. While cold chain logistics remain a challenge, advancements in vaccine formulation and storage are improving accessibility, ensuring effective immunization coverage in remote and underserved areas. LAVs' high immunogenicity continues to make them a preferred option in global disease eradication efforts.

What Innovations Are Enhancing Live Attenuated Vaccines?

Ongoing advancements in vaccine technology are improving the safety, efficacy, and distribution of live attenuated vaccines. One major innovation is the application of reverse genetics, which allows scientists to modify viral genomes for enhanced stability while maintaining immunogenicity. Additionally, next-generation vaccine vectors are reducing the risk of reversion to virulence, addressing concerns over LAV safety. Improved adjuvants and delivery mechanisms, including microneedle patches and mucosal vaccines, are enhancing vaccine administration efficiency. Artificial intelligence (AI) and big data analytics are expediting vaccine design by identifying optimal antigenic targets. Freeze-dried and thermostable formulations are addressing cold chain limitations, extending shelf life, and improving distribution in low-resource regions. Advances in synthetic biology are also refining vaccine attenuation techniques, ensuring greater safety while preserving immunogenic properties. The increasing development of combination vaccines, offering protection against multiple diseases in a single dose, is further driving LAV market expansion by improving compliance and coverage.

How Is Market Demand and Consumer Perception Shaping Growth?

Consumer confidence in vaccines and immunization programs significantly impacts the adoption of live attenuated vaccines. The success of LAVs in eradicating diseases such as smallpox and controlling polio has reinforced their credibility, supporting widespread inclusion in national immunization programs. However, vaccine hesitancy, driven by misinformation and safety concerns, poses a challenge in certain regions. Governments and health organizations are actively combating misinformation with educational campaigns and transparent communication regarding vaccine benefits and safety. The COVID-19 pandemic has further emphasized the importance of vaccine preparedness, increasing investment in both new and existing LAV platforms. Global immunization initiatives, such as those led by Gavi and WHO, have bolstered vaccine accessibility in low-income countries. Travel vaccines and increasing international mobility are also contributing to LAV demand, particularly for yellow fever and typhoid. The trend toward personalized medicine and targeted immunization strategies is further influencing consumer expectations, driving research into more precise, immune-responsive vaccines.

What Are the Key Growth Drivers Fueling the Market?

The growth in the live attenuated vaccines market is driven by several factors, including rising disease prevalence, expanding immunization programs, and technological advancements. Increasing cases of infectious diseases, particularly in developing regions, are creating higher demand for effective vaccines. Governments and global health organizations are prioritizing vaccination programs, often making LAVs mandatory for routine immunization schedules. The cost-effectiveness of live attenuated vaccines compared to inactivated or recombinant alternatives is another major driver, as healthcare systems seek efficient disease prevention solutions. Ongoing research in vaccine development, backed by public and private investments, is leading to the creation of novel LAV formulations with improved stability and safety. The growing preference for combination vaccines is also accelerating market growth by simplifying immunization schedules and improving adherence rates. Advances in cold chain logistics, including portable vaccine carriers and thermostable formulations, are enhancing vaccine distribution in resource-limited areas. The heightened focus on pandemic preparedness and rapid vaccine development is further driving innovation in LAV platforms. With these growth drivers in place, the live attenuated vaccines market is poised for sustained expansion, playing a vital role in global disease prevention and health security.

SCOPE OF STUDY:

The report analyzes the Live Attenuated Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Bacterial vaccine, Viral vaccine); Development (Tissue culture, Embryonated eggs, Live animals); Administration Route (Oral, Injectable, Intranasal); Age Group (Pediatric, Adult); Indication (Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza, Other indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech International Limited
  • Bio-Med Limited
  • BioDiem Ltd
  • Boehringer Ingelheim International GmbH
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc (GSK)
  • Haffkine Biopharmaceutical Corporation Ltd.
  • Johnson & Johnson
  • Meissa Vaccines
  • Merck & Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP31867

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Live Attenuated Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Durable and Broad-Spectrum Immunity Drives Demand for Live Attenuated Vaccines
    • Expansion of National Immunization Programs Throws the Spotlight on Cost-Effective Live Vaccine Platforms
    • OEM Innovation in Cold Chain-Free Live Attenuated Formulations Strengthens Use in Remote and Low-Infrastructure Regions
    • Increased Application in Viral and Bacterial Disease Prevention Spurs Growth in Global Pediatric Vaccine Markets
    • Rising Adoption in Zoonotic and Vector-Borne Disease Vaccination Drives Demand in Emerging Markets
    • OEM Development of Thermostable and Single-Dose Live Vaccines Enhances Accessibility in Tropical Climates
    • Growth in Clinical Trials Targeting Mucosal Immunity Expands Use of Intranasal Live Attenuated Vaccines
    • OEM Partnerships With Global Health Organizations Accelerate Distribution in Mass Immunization Campaigns
    • Surge in Travel and Migrant Populations Strengthens Business Case for Rapid-Response Live Vaccination Programs
    • Regulatory Support for Emergency Use Authorizations Expands Opportunities for Rapid Deployment in Outbreaks
    • Increasing Interest in Multivalent Live Attenuated Platforms Supports Combination Vaccine Development
    • Rising Acceptance of Viral Vector-Based Live Platforms Propels Innovation in Oncology and Chronic Infection Prevention
    • OEM Focus on Recombinant DNA Techniques Enhances Safety Profiles and Genetic Stability in Live Vaccines
    • Expansion of Veterinary Live Attenuated Vaccines Strengthens Cross-Sector Market Penetration
    • Widespread Use in Livestock Disease Management Drives Adoption in Animal Health and Agri-Tech Industries
    • OEM Investment in Spray and Edible Vaccine Delivery Mechanisms Supports Non-Invasive Immunization Models
    • Global Support for Vaccine Equity and Affordability Propels Demand for Established Live Attenuated Manufacturing Processes
    • Focus on Long-Term Immune Memory and T-Cell Response Reinforces Immunological Value of Live Attenuated Approaches
    • Challenges in Cold Chain Storage and Strain Mutation Drive Research in Stabilization and Attenuation Techniques
    • Growing Threat of Antimicrobial Resistance Supports Prophylactic Deployment of Live Vaccines in High-Risk Areas
    • Surge in Pandemic Preparedness Funding Enhances Commercial Viability of Broad-Spectrum Live Vaccine Pipelines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Live Attenuated Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Live Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Live Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Bacterial vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Bacterial vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Bacterial vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Viral vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Viral vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Viral vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Tuberculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Tuberculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Tuberculosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Measles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Measles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Measles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Rotavirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Rotavirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Rotavirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Yellow fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Yellow fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Yellow fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral polio by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral polio by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oral polio by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Influenza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Tissue culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Tissue culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Tissue culture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Embryonated eggs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Embryonated eggs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Embryonated eggs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Live animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Live animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Live animals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: USA 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Canada 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Canada 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • JAPAN
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Japan 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Japan Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Japan 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • CHINA
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 101: China Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: China 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: China 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 113: China Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: China Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: China 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • EUROPE
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Live Attenuated Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Live Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Europe 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Europe 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 128: Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Europe Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Europe 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 131: Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Europe Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Europe 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • FRANCE
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 134: France Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: France 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: France 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 140: France Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: France Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: France 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 143: France Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: France Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: France 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 146: France Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: France Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: France 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • GERMANY
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Germany 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 152: Germany Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Germany Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Germany 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 155: Germany Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Germany Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Germany 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 158: Germany Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Germany Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Germany 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 161: Germany Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Germany Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Germany 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 164: Italy Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Italy Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Italy 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Italy Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Italy Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Italy 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 170: Italy Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Italy Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Italy 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 173: Italy Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Italy Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Italy 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 176: Italy Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Italy Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Italy 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 179: UK Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: UK Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: UK 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: UK Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: UK Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: UK 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 185: UK Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UK Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: UK 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 188: UK Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UK Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UK 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 191: UK Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UK Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UK 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 194: Spain Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Spain Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Spain 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 197: Spain Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Spain Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Spain 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 200: Spain Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Spain Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Spain 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 203: Spain Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Spain Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Spain 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 206: Spain Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Spain Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Spain 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 209: Russia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Russia Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Russia 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 212: Russia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Russia Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Russia 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 215: Russia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Russia Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Russia 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 218: Russia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Russia Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Russia 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 221: Russia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Russia Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Russia 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Europe Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Europe 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Europe Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Europe 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Europe Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Europe 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Europe Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Europe 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Europe Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Europe 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Asia-Pacific Historic Review for Live Attenuated Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Asia-Pacific Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Asia-Pacific Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Asia-Pacific Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Asia-Pacific Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Asia-Pacific Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 257: Australia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Australia Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Australia 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 260: Australia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Australia Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Australia 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 263: Australia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Australia Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Australia 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 266: Australia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Australia Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Australia 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 269: Australia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Australia Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Australia 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • INDIA
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 272: India Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: India Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: India 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 275: India Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: India Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: India 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 278: India Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: India Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: India 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 281: India Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: India Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: India 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 284: India Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: India Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: India 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 287: South Korea Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: South Korea Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: South Korea 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 290: South Korea Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: South Korea Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: South Korea 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 293: South Korea Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: South Korea Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: South Korea 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 296: South Korea Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: South Korea Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: South Korea 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 299: South Korea Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: South Korea Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: South Korea 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Asia-Pacific Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Asia-Pacific Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Asia-Pacific Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Asia-Pacific Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Asia-Pacific Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Asia-Pacific 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 317: Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 318: Latin America Historic Review for Live Attenuated Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Latin America 15-Year Perspective for Live Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 320: Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Latin America Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Latin America 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 323: Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Latin America Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Latin America 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 326: Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Latin America Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Latin America 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 329: Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Latin America Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Latin America 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 332: Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Latin America Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Latin America 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 335: Argentina Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Argentina Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Argentina 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 338: Argentina Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Argentina Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Argentina 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 341: Argentina Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Argentina Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Argentina 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 344: Argentina Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Argentina Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Argentina 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 347: Argentina Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Argentina Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Argentina 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 350: Brazil Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Brazil Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Brazil 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 353: Brazil Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Brazil Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Brazil 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 356: Brazil Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Brazil Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Brazil 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 359: Brazil Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Brazil Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Brazil 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 362: Brazil Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Brazil Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Brazil 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 365: Mexico Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Mexico Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Mexico 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 368: Mexico Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Mexico Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Mexico 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 371: Mexico Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Mexico Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Mexico 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 374: Mexico Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Mexico Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Mexico 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 377: Mexico Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Mexico Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Mexico 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Latin America Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Latin America 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Latin America Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Latin America 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Latin America Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Latin America 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Latin America Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Latin America 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Latin America Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Latin America 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 395: Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 396: Middle East Historic Review for Live Attenuated Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Middle East 15-Year Perspective for Live Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 398: Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Middle East Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Middle East 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 401: Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Middle East Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Middle East 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 404: Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Middle East Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Middle East 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 407: Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Middle East Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Middle East 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 410: Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Middle East Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Middle East 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 413: Iran Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Iran Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Iran 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 416: Iran Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Iran Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 418: Iran 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 419: Iran Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Iran Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 421: Iran 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 422: Iran Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Iran Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 424: Iran 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 425: Iran Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Iran Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 427: Iran 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 428: Israel Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Israel Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 430: Israel 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 431: Israel Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Israel Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 433: Israel 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 434: Israel Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Israel Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 436: Israel 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 437: Israel Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 438: Israel Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 439: Israel 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 440: Israel Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 441: Israel Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 442: Israel 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 444: Saudi Arabia Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 445: Saudi Arabia 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 447: Saudi Arabia Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 448: Saudi Arabia 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 450: Saudi Arabia Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 451: Saudi Arabia 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 453: Saudi Arabia Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 454: Saudi Arabia 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 456: Saudi Arabia Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 457: Saudi Arabia 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 458: UAE Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 459: UAE Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 460: UAE 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 461: UAE Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 462: UAE Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 463: UAE 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 464: UAE Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 465: UAE Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 466: UAE 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 467: UAE Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 468: UAE Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 469: UAE 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 470: UAE Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 471: UAE Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 472: UAE 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 474: Rest of Middle East Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 475: Rest of Middle East 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 477: Rest of Middle East Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 478: Rest of Middle East 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Rest of Middle East Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 481: Rest of Middle East 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 483: Rest of Middle East Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 484: Rest of Middle East 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 486: Rest of Middle East Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 487: Rest of Middle East 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030
  • AFRICA
    • Live Attenuated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 488: Africa Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 489: Africa Historic Review for Live Attenuated Vaccines by Vaccine Type - Bacterial vaccine and Viral vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 490: Africa 15-Year Perspective for Live Attenuated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Bacterial vaccine and Viral vaccine for the Years 2015, 2025 & 2030
    • TABLE 491: Africa Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Age Group - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 492: Africa Historic Review for Live Attenuated Vaccines by Age Group - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 493: Africa 15-Year Perspective for Live Attenuated Vaccines by Age Group - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2015, 2025 & 2030
    • TABLE 494: Africa Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 495: Africa Historic Review for Live Attenuated Vaccines by Indication - Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 496: Africa 15-Year Perspective for Live Attenuated Vaccines by Indication - Percentage Breakdown of Value Sales for Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza and Other indications for the Years 2015, 2025 & 2030
    • TABLE 497: Africa Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 498: Africa Historic Review for Live Attenuated Vaccines by Development - Tissue culture, Embryonated eggs and Live animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 499: Africa 15-Year Perspective for Live Attenuated Vaccines by Development - Percentage Breakdown of Value Sales for Tissue culture, Embryonated eggs and Live animals for the Years 2015, 2025 & 2030
    • TABLE 500: Africa Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 501: Africa Historic Review for Live Attenuated Vaccines by Administration Route - Oral, Injectable and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 502: Africa 15-Year Perspective for Live Attenuated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Intranasal for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!